These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23483542)

  • 61. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.
    Popiel HA; Takeuchi T; Burke JR; Strittmatter WJ; Toda T; Wada K; Nagai Y
    Neurotherapeutics; 2013 Jul; 10(3):440-6. PubMed ID: 23504628
    [TBL] [Abstract][Full Text] [Related]  

  • 62. BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1.
    Ding Y; Adachi H; Katsuno M; Sahashi K; Kondo N; Iida M; Tohnai G; Nakatsuji H; Sobue G
    Neuroscience; 2016 Jul; 327():20-31. PubMed ID: 27058144
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genes and pathways affected by CAG-repeat RNA-based toxicity in Drosophila.
    Shieh SY; Bonini NM
    Hum Mol Genet; 2011 Dec; 20(24):4810-21. PubMed ID: 21933837
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1.
    Meriin AB; Zhang X; He X; Newnam GP; Chernoff YO; Sherman MY
    J Cell Biol; 2002 Jun; 157(6):997-1004. PubMed ID: 12058016
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synergistic activation of AMPK prevents from polyglutamine-induced toxicity in Caenorhabditis elegans.
    Gómez-Escribano AP; Bono-Yagüe J; García-Gimeno MA; Sequedo MD; Hervás D; Fornés-Ferrer V; Torres-Sánchez SC; Millán JM; Sanz P; Vázquez-Manrique RP
    Pharmacol Res; 2020 Nov; 161():105105. PubMed ID: 32739430
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model.
    Weiss KR; Kimura Y; Lee WC; Littleton JT
    Genetics; 2012 Feb; 190(2):581-600. PubMed ID: 22095086
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y; Popiel HA
    Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reduction of polyglutamine toxicity by TDP-43, FUS and progranulin in Huntington's disease models.
    Tauffenberger A; Chitramuthu BP; Bateman A; Bennett HP; Parker JA
    Hum Mol Genet; 2013 Feb; 22(4):782-94. PubMed ID: 23172908
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neurodegeneration caused by polyglutamine expansion is regulated by P-glycoprotein in Drosophila melanogaster.
    Yadav S; Tapadia MG
    Genetics; 2013 Nov; 195(3):857-70. PubMed ID: 24037265
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Association of polyalanine and polyglutamine coiled coils mediates expansion disease-related protein aggregation and dysfunction.
    Pelassa I; Corà D; Cesano F; Monje FJ; Montarolo PG; Fiumara F
    Hum Mol Genet; 2014 Jul; 23(13):3402-20. PubMed ID: 24497578
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vitro aggregating β-lactamase-polyQ chimeras do not induce toxic effects in an in vivo Caenorhabditis elegans model.
    Van Assche R; Borghgraef C; Vaneyck J; Dumoulin M; Schoofs L; Temmerman L
    J Negat Results Biomed; 2017 Aug; 16(1):14. PubMed ID: 28830560
    [TBL] [Abstract][Full Text] [Related]  

  • 72. SCA1-phosphorylation, a regulator of Ataxin-1 function and pathogenesis.
    Orr HT
    Prog Neurobiol; 2012 Dec; 99(3):179-85. PubMed ID: 22531670
    [TBL] [Abstract][Full Text] [Related]  

  • 73. FipoQ/FBXO33, a Cullin-1-based ubiquitin ligase complex component modulates ubiquitination and solubility of polyglutamine disease protein.
    Chen ZS; Wong AKY; Cheng TC; Koon AC; Chan HYE
    J Neurochem; 2019 Jun; 149(6):781-798. PubMed ID: 30685895
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds.
    Li Z; Wang C; Wang Z; Zhu C; Li J; Sha T; Ma L; Gao C; Yang Y; Sun Y; Wang J; Sun X; Lu C; Difiglia M; Mei Y; Ding C; Luo S; Dang Y; Ding Y; Fei Y; Lu B
    Nature; 2019 Nov; 575(7781):203-209. PubMed ID: 31666698
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors.
    Margulis BA; Vigont V; Lazarev VF; Kaznacheyeva EV; Guzhova IV
    FEBS Lett; 2013 Jun; 587(13):1997-2007. PubMed ID: 23684638
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans.
    Morley JF; Brignull HR; Weyers JJ; Morimoto RI
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10417-22. PubMed ID: 12122205
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila.
    Marsh JL; Walker H; Theisen H; Zhu YZ; Fielder T; Purcell J; Thompson LM
    Hum Mol Genet; 2000 Jan; 9(1):13-25. PubMed ID: 10587574
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nuclear accumulation of polyglutamine disease proteins and neuropathology.
    Havel LS; Li S; Li XJ
    Mol Brain; 2009 Jul; 2():21. PubMed ID: 19575804
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.
    Hart MP; Gitler AD
    J Neurosci; 2012 Jul; 32(27):9133-42. PubMed ID: 22764223
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ataxin-2 mediated cell death is dependent on domains downstream of the polyQ repeat.
    Ng H; Pulst SM; Huynh DP
    Exp Neurol; 2007 Dec; 208(2):207-15. PubMed ID: 17949716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.